Which has higher valuation and earnings, NVAX or MRNA?

Novavax has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.88 $440.30M -$1.52 N/A Moderna $1.94B 44.41 -$2.82B -$7.99 N/A

Is NVAX or MRNA more profitable?

Novavax has a net margin of -59.87% compared to Moderna's net margin of -141.43%. Novavax's return on equity of -14.82% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -59.87% -14.82% -13.35% Moderna -141.43% -28.30% -19.39%

Does the media prefer NVAX or MRNA?

In the previous week, Moderna had 46 more articles in the media than Novavax. MarketBeat recorded 60 mentions for Moderna and 14 mentions for Novavax. Moderna's average media sentiment score of 0.19 beat Novavax's score of -0.07 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Neutral Moderna 19 Very Positive mention(s) 14 Positive mention(s) 14 Neutral mention(s) 4 Negative mention(s) 7 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, OCGN or NVAX?

Novavax has higher revenue and earnings than Ocugen. Novavax is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ocugen $4.41M 68.08 -$67.85M -$0.26 N/A Novavax $1.12B 1.88 $440.30M -$1.52 N/A

Is OCGN or NVAX more profitable?

Ocugen has a net margin of 0.00% compared to Novavax's net margin of -59.87%. Novavax's return on equity of -14.82% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen N/A -127,987.80% -115.95% Novavax -59.87% -14.82% -13.35%

Does the media favor OCGN or NVAX?

In the previous week, Novavax had 9 more articles in the media than Ocugen. MarketBeat recorded 14 mentions for Novavax and 5 mentions for Ocugen. Ocugen's average media sentiment score of 0.95 beat Novavax's score of -0.07 indicating that Ocugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novavax 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Neutral

Which has higher earnings and valuation, AZN or NVAX?

Astrazeneca has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrazeneca $58.74B 4.12 $10.23B $6.69 23.31 Novavax $1.12B 1.88 $440.30M -$1.52 N/A

Is AZN or NVAX more profitable?

Astrazeneca has a net margin of 17.02% compared to Novavax's net margin of -59.87%. Astrazeneca's return on equity of 31.45% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Astrazeneca 17.02% 31.45% 13.20% Novavax -59.87% -14.82% -13.35%

Does the media refer more to AZN or NVAX?

In the previous week, Astrazeneca had 11 more articles in the media than Novavax. MarketBeat recorded 25 mentions for Astrazeneca and 14 mentions for Novavax. Astrazeneca's average media sentiment score of 0.53 beat Novavax's score of -0.07 indicating that Astrazeneca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 10 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Novavax 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Neutral

Which has better earnings & valuation, JNJ or NVAX?

Johnson & Johnson has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Johnson & Johnson $94.19B 6.37 $26.80B $8.63 28.84 Novavax $1.12B 1.88 $440.30M -$1.52 N/A

Is JNJ or NVAX more profitable?

Johnson & Johnson has a net margin of 21.48% compared to Novavax's net margin of -59.87%. Johnson & Johnson's return on equity of 32.42% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Johnson & Johnson 21.48% 32.42% 13.35% Novavax -59.87% -14.82% -13.35%

Does the media favor JNJ or NVAX?

In the previous week, Johnson & Johnson had 113 more articles in the media than Novavax. MarketBeat recorded 127 mentions for Johnson & Johnson and 14 mentions for Novavax. Johnson & Johnson's average media sentiment score of 0.57 beat Novavax's score of -0.07 indicating that Johnson & Johnson is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Johnson & Johnson 46 Very Positive mention(s) 25 Positive mention(s) 31 Neutral mention(s) 14 Negative mention(s) 6 Very Negative mention(s) Positive Novavax 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, PFE or NVAX?

Pfizer has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pfizer $62.58B 2.59 $7.77B $0.76 37.36 Novavax $1.12B 1.88 $440.30M -$1.52 N/A

Is PFE or NVAX more profitable?

Pfizer has a net margin of 6.80% compared to Novavax's net margin of -59.87%. Pfizer's return on equity of 19.63% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Pfizer 6.80% 19.63% 8.46% Novavax -59.87% -14.82% -13.35%

Does the media refer more to PFE or NVAX?

In the previous week, Pfizer had 70 more articles in the media than Novavax. MarketBeat recorded 84 mentions for Pfizer and 14 mentions for Novavax. Pfizer's average media sentiment score of 0.49 beat Novavax's score of -0.07 indicating that Pfizer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 29 Very Positive mention(s) 13 Positive mention(s) 21 Neutral mention(s) 14 Negative mention(s) 3 Very Negative mention(s) Neutral Novavax 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Neutral

Novavax (NVAX) Competitors

$12.82 +0.16 (+1.26%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$12.82 +0.00 (+0.04%)

As of 10/13/2026 07:59 PM Eastern

Compare

NVAX vs. MRNA, OCGN, AZN, JNJ, and PFE

Should you buy Novavax stock or one of its competitors? Novavax's main competitors and comparable companies include Moderna (MRNA), Ocugen (OCGN), Astrazeneca (AZN), Johnson & Johnson (JNJ), and Pfizer (PFE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Novavax compare to Moderna?

Novavax (NASDAQ:NVAX) and Moderna (NASDAQ:MRNA) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Novavax has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.88	$440.30M	-$1.52	N/A
Moderna	$1.94B	44.41	-$2.82B	-$7.99	N/A

In the previous week, Moderna had 46 more articles in the media than Novavax. MarketBeat recorded 60 mentions for Moderna and 14 mentions for Novavax. Moderna's average media sentiment score of 0.19 beat Novavax's score of -0.07 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Neutral
Moderna	19 Very Positive mention(s)	14 Positive mention(s)	14 Neutral mention(s)	4 Negative mention(s)	7 Very Negative mention(s)	Neutral

Novavax has a beta of 2.44, indicating that its stock price is 144% more volatile than the broader market. Comparatively, Moderna has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market.

Novavax has a net margin of -59.87% compared to Moderna's net margin of -141.43%. Novavax's return on equity of -14.82% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-59.87%	-14.82%	-13.35%
Moderna	-141.43%	-28.30%	-19.39%

53.0% of Novavax shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 1.6% of Novavax shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Novavax currently has a consensus price target of $14.00, indicating a potential upside of 9.20%. Moderna has a consensus price target of $100.60, indicating a potential downside of 53.48%. Given Novavax's stronger consensus rating and higher probable upside, research analysts plainly believe Novavax is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Moderna	4 Sell rating(s)	15 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.12

Summary

Novavax beats Moderna on 8 of the 15 factors compared between the two stocks.

How does Novavax compare to Ocugen?

Ocugen (NASDAQ:OCGN) and Novavax (NASDAQ:NVAX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

Ocugen has a net margin of 0.00% compared to Novavax's net margin of -59.87%. Novavax's return on equity of -14.82% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	N/A	-127,987.80%	-115.95%
Novavax	-59.87%	-14.82%	-13.35%

Novavax has higher revenue and earnings than Ocugen. Novavax is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	68.08	-$67.85M	-$0.26	N/A
Novavax	$1.12B	1.88	$440.30M	-$1.52	N/A

Ocugen has a beta of 2.27, meaning that its stock price is 127% more volatile than the broader market. Comparatively, Novavax has a beta of 2.44, meaning that its stock price is 144% more volatile than the broader market.

10.3% of Ocugen shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 4.0% of Ocugen shares are owned by company insiders. Comparatively, 1.6% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Ocugen currently has a consensus target price of $9.50, indicating a potential upside of 972.96%. Novavax has a consensus target price of $14.00, indicating a potential upside of 9.20%. Given Ocugen's stronger consensus rating and higher possible upside, equities analysts clearly believe Ocugen is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Novavax had 9 more articles in the media than Ocugen. MarketBeat recorded 14 mentions for Novavax and 5 mentions for Ocugen. Ocugen's average media sentiment score of 0.95 beat Novavax's score of -0.07 indicating that Ocugen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocugen	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Neutral

Summary

Novavax beats Ocugen on 8 of the 15 factors compared between the two stocks.

How does Novavax compare to Astrazeneca?

Astrazeneca (NYSE:AZN) and Novavax (NASDAQ:NVAX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

Astrazeneca presently has a consensus price target of $206.67, indicating a potential upside of 32.53%. Novavax has a consensus price target of $14.00, indicating a potential upside of 9.20%. Given Astrazeneca's stronger consensus rating and higher probable upside, research analysts clearly believe Astrazeneca is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.74
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Astrazeneca had 11 more articles in the media than Novavax. MarketBeat recorded 25 mentions for Astrazeneca and 14 mentions for Novavax. Astrazeneca's average media sentiment score of 0.53 beat Novavax's score of -0.07 indicating that Astrazeneca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	10 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
Novavax	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Neutral

Astrazeneca has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market. Comparatively, Novavax has a beta of 2.44, meaning that its stock price is 144% more volatile than the broader market.

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 1.6% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Astrazeneca has a net margin of 17.02% compared to Novavax's net margin of -59.87%. Astrazeneca's return on equity of 31.45% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.02%	31.45%	13.20%
Novavax	-59.87%	-14.82%	-13.35%

Astrazeneca has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.12	$10.23B	$6.69	23.31
Novavax	$1.12B	1.88	$440.30M	-$1.52	N/A

Summary

Astrazeneca beats Novavax on 12 of the 15 factors compared between the two stocks.

How does Novavax compare to Johnson & Johnson?

Johnson & Johnson (NYSE:JNJ) and Novavax (NASDAQ:NVAX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Johnson & Johnson has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$94.19B	6.37	$26.80B	$8.63	28.84
Novavax	$1.12B	1.88	$440.30M	-$1.52	N/A

In the previous week, Johnson & Johnson had 113 more articles in the media than Novavax. MarketBeat recorded 127 mentions for Johnson & Johnson and 14 mentions for Novavax. Johnson & Johnson's average media sentiment score of 0.57 beat Novavax's score of -0.07 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	46 Very Positive mention(s)	25 Positive mention(s)	31 Neutral mention(s)	14 Negative mention(s)	6 Very Negative mention(s)	Positive
Novavax	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Neutral

Johnson & Johnson currently has a consensus price target of $276.22, suggesting a potential upside of 10.97%. Novavax has a consensus price target of $14.00, suggesting a potential upside of 9.20%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, equities analysts clearly believe Johnson & Johnson is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.80
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Johnson & Johnson has a net margin of 21.48% compared to Novavax's net margin of -59.87%. Johnson & Johnson's return on equity of 32.42% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	21.48%	32.42%	13.35%
Novavax	-59.87%	-14.82%	-13.35%

Johnson & Johnson has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market. Comparatively, Novavax has a beta of 2.44, indicating that its stock price is 144% more volatile than the broader market.

69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by company insiders. Comparatively, 1.6% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Johnson & Johnson beats Novavax on 14 of the 16 factors compared between the two stocks.

How does Novavax compare to Pfizer?

Pfizer (NYSE:PFE) and Novavax (NASDAQ:NVAX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Pfizer presently has a consensus target price of $28.72, suggesting a potential upside of 1.15%. Novavax has a consensus target price of $14.00, suggesting a potential upside of 9.20%. Given Novavax's stronger consensus rating and higher possible upside, analysts plainly believe Novavax is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	14 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.14
Novavax	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

68.4% of Pfizer shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 0.6% of Pfizer shares are owned by insiders. Comparatively, 1.6% of Novavax shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Pfizer has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.59	$7.77B	$0.76	37.36
Novavax	$1.12B	1.88	$440.30M	-$1.52	N/A

Pfizer has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, Novavax has a beta of 2.44, indicating that its stock price is 144% more volatile than the broader market.

In the previous week, Pfizer had 70 more articles in the media than Novavax. MarketBeat recorded 84 mentions for Pfizer and 14 mentions for Novavax. Pfizer's average media sentiment score of 0.49 beat Novavax's score of -0.07 indicating that Pfizer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	29 Very Positive mention(s)	13 Positive mention(s)	21 Neutral mention(s)	14 Negative mention(s)	3 Very Negative mention(s)	Neutral
Novavax	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Neutral

Pfizer has a net margin of 6.80% compared to Novavax's net margin of -59.87%. Pfizer's return on equity of 19.63% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	6.80%	19.63%	8.46%
Novavax	-59.87%	-14.82%	-13.35%

Summary

Pfizer beats Novavax on 10 of the 14 factors compared between the two stocks.

Get Novavax News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVAX vs. The Competition

Export

Metric	Novavax	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.09B	$3.93B	$7.27B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	N/A	10.00	196.87	19.42
Price / Sales	1.88	1,149.11	562.72	81.54
Price / Cash	3.61	118.50	77.16	53.04
Price / Book	-16.23	16.95	10.71	6.03
Net Income	$440.30M	-$22.69M	$3.50B	$380.34M
7 Day Performance	14.26%	-4.44%	-2.90%	-2.32%
1 Month Performance	33.68%	-12.51%	-7.38%	-5.29%
1 Year Performance	44.21%	7.77%	3.04%	-2.94%

Novavax Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVAX Novavax	1.5377 of 5 stars	$12.82 +1.3%	$14.00 +9.2%	+48.7%	$2.09B	$1.12B	N/A	749
MRNA Moderna	1.7556 of 5 stars	$203.21 +6.9%	$77.83 -61.7%	+708.7%	$81.13B	$1.94B	N/A	4,700	Trending News Gap Down
OCGN Ocugen	1.952 of 5 stars	$1.04 +2.0%	$9.50 +813.5%	-44.7%	$352.67M	$4.41M	N/A	116	Insider Trade
AZN Astrazeneca	4.8499 of 5 stars	$156.50 -0.3%	$206.67 +32.1%	-7.7%	$242.72B	$58.74B	23.39	96,100	Trending News Analyst Downgrade Analyst Revision
JNJ Johnson & Johnson	4.5631 of 5 stars	$252.90 -1.2%	$276.09 +9.2%	+30.4%	$609.45B	$94.19B	29.30	138,200	Trending News Earnings Report Dividend Announcement Analyst Revision Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NVAX) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novavax (NVAX) Competitors